iECURE, a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, and Center for Breakthrough Medicines (CBM), have entered into a collaboration wherein CBM will produce and supply good manufacturing practices (GMP)-grade adeno-associated virus (AAV) for use in iECURE’s future clinical studies.

“Our approach to gene editing relies on highly complex manufacturing processes, and we are eager to establish partnerships to ensure a reliable supply of GMP materials for future clinical development,” said Paul Firuta, chief operating officer, iECURE. “CBM was able to offer us significant amount of guaranteed capacity with scheduling flexibility and we are confident that they will be a strong partner with their state-of-the-art facilities and end-to end capabilities.”

Audrey Greenberg, chief business officer and co-founder of CBM, said, “iECURE’s approach to gene editing is quite innovative and has the potential to bring significant hope to patients and families facing devastating diagnoses. Our ability to provide customizable clinical and commercial GMP manufacturing solutions integrated with industry-leading comprehensive in-process testing, quality control, and lot release programs allows us to support our partners like iECURE through the entirety of their product lifecycle and is aligned with our mission to bring life changing medicines to patients in need.”